Pharma Focus Asia
KP - Choose our fully recyclable blister films

Telisotuzumab Vedotin (Teliso-V) Developed for the Treatment of Non-Small Cell Lung Cancer

AbbVie developed Telisotuzumab Vedotin (Teliso-V) an investigational antibody-drug conjugate (ADC), to treat patients with non-small cell lung cancer (NSCLC).

(Teliso-V) is used to treat patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) consisting of high levels of c-Met overexpression whose disease has advanced on or after platinum-based therapy.

Patients undergoing standard of care therapies, including prior platinum have limited treatment options and poor prognosis.

Currently there are no approved cancer therapies specifically for patients with c-Met overexpressing NSCLC. Teliso-V i in combination with osimertinib is being evaluated in the ongoing Phase 1 study M14-237 in patients with previously treated c-Met overexpressing NSCLC.

U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to investigational telisotuzumab vedotin (Teliso-V) for previously treated non-small cell lung cancer.

In U.S and worldwide, although having advanced treatments options lung cancer remains the most common type of cancer among both men and women. Moreover, it is the third most common cancer in females and affecting males. Approximately 85% of lung cancers are classified as NSCLC.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024